Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area

Phase 1TerminatedNCT00528294

University Hospital, Ghent12 enrolled

Overview

This trials examines the feasibility of GRID-therapy combined with biologically imaging based IMRT (BG-IMRT). Within this trial, the strict toxicity parameters of primary treatment of head and neck tumors are used. The GRID and BG-IMRT technique might be possible to reduce the total radiation dose 2 to 3 times.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Head and Neck Tumors

Interventions

GRID radiotherapyRADIATION

GRID-radiotherapy followed by biological imaging guided IMRT

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Recurrent or new head or neck tumor * 18 years or older

Locations (1)

University Hospital Ghent

Ghent, Belgium

Outcomes

Primary Outcomes

Maximum tolerated dose.

Time frame: 3 months after end of treatment

Superior local control with Grid 18F-FDG-PET BG-IMRT using previously obtained maximum tolerated dose.

Time frame: 1 year.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.